共 7 条
[4]
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy[J] . Karin Jordan,Iris Kinitz,Wieland Voigt,Timo Behlendorf,Hans-Heinrich Wolf,Hans-Joachim Schmoll.European Journal of Cancer . 2008 (7)
[5]
The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials[J] . David G. Warr,Steven M. Grunberg,Richard J. Gralla,Paul J. Hesketh,Fausto Roila,Ronald de Wit,Alexandra D. Carides,Arlene Taylor,Judith K. Evans,Kevin J. Horgan.European Journal of Cancer . 2005 (9)
[6]
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist[J] . PeterEisenberg,JazminFigueroa‐Vadillo,RosalioZamora,VeenaCharu,JulioHajdenberg,AlanCartmell,AlbertoMacciocchi,StevenGrunberg.Cancer . 2003 (11)
[7]
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology .2 Gralla R J,Osoba D,Kris M G,Kirkbride P,Hesketh P J,Chinnery L W,Clark-Snow R,Gill D P,Groshen S,Grunberg S,Koeller J M,Morrow G R,Perez E A,Silber J H,Pfister D G. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 1999